Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins

Antiviral Therapy

Volumn 13, Issue 2, 2008, Pages 221-230

  Chin, Ruth ^a   Earnest Silveira, Linda ^a   Koeberlein, Bernd ^b   Franz, Susanne ^c   Zentgraf, Hanswalter ^c   Bowden, Scott ^d   Bock, C Thomas ^b   Torresi, Joseph ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; GLYCOGEN SYNTHASE KINASE 3BETA; LAMIVUDINE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN KINASE B; PROTEIN P53; REGULATOR PROTEIN;

ADENOVIRUS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; CELL CYCLE PROTEINS; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 42149159013     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
2. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22:5093-5107.
3. Feitelson MA, Reis HM, Liu J, Lian Z, Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci 2005; 10:1558-1572.
4. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19:670-675.
5. Chen C-J, Yang H-I, Jun S, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
6. Liu C-J, Kao J-H, Chen D-S. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25:1097-1107.
7. Song L, Toan N, Duy D, et al. Impact of the hepatitis B virus genotype and genotype-mixtures on the course of liver disease in Vietnam. Hepatology 2006; 43:1375-1384.
8. Crockett S, Keeffe E. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005; 4:1-12.
9. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3:57-62.
10. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic nepatitis B in Asians: therapeutic implications. Gut 2005; 54:1610-1614.
11. Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 2006; 80:4406-4414.
12. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996; 70:4978-4985.
13. Tarn C, Zou L, Hullinger RL, Andrisani OM. Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol 2002; 76:9763-9772.
14. Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001; 276:34671-34680.
15. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the nepatitis B virus X gene-transfected cells. Oncogene 1997; 15:1895-1901.
16. Branda M, Wands J. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006; 43:891-902.
17. Weil R, Sirma H, Giannini C, et al. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol 1999; 19:6345-6354.
18. Chin R, Earnest-Silveira L, Koeberlein B, et al. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatology 2007; 47:325-337.
19. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-759.
20. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
21. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005; 10:431-439.
22. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
24. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
25. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-891.
26. Iloeje HU, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Prediciting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95:2509-2514.
28. Bowden S, Jackson K, Littlejohn M, Locarnini S. Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med 2004; 95:41-50.
29. Choudhari SR, Khan MA, Harris G, et al. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 2007; 6:112-121.
30. Schoniger-Hekele M, Hanel S, Wrba F, Muller C. Hepatocellular carcinoma - survival andclinical characteristics in relation to various histologic molecular markers in Western patients. Liv Int 2005; 25:62-69.
31. Wagayama H, Shiraki K, Sugimoto K, et al. High expression of p21waf1/cip1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol 2002; 33:429-434.
32. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
33. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21cip/waf1 enhances protein stability of p21cip/waf1 and promotes cell survival. J Biol Chem 2002; 277:11352-11361.
34. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-Dependent Phosphorylation of p21Cip1 Regulates PCNA Binding and Proliferation of Endothelial Cells. Mol Cell Biol 2001; 21:5644-5657.
35. Mullany LK, Nelsen CJ, Hanse EA, et al. AKT-mediated liver growth promotes induction of cyclin E through a novel mechanism and a p21-mediated cell cycle arrest. J Biol Chem 2007; 282:21244-21252.
36. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005; 229:157-169.
37. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-990.
38. Bannasch P, Klimek F, Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 1997; 29:303-313.
39. Su Q, Benner A, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 1997; 431:391-406.
40. Bannasch P, Jahn U-R, Hacker HJ, et al. Focal hepatic glycogenosis: a putative preneoplastic lesion associated with neoplasia and cirrhosis in explanted human livers. Int J Oncol 1997; 10:261-268.
41. Bannasch P, Haertel T, Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 2003; 31:134-139.
42. Evert M, Sun J, Pichler S, Slavova N, Schneider-Stock R, Dombrowski F. Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats. Cancer Res 2004; 64:8093-8100.
43. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997; 26:598-604.
44. Smith KT, Campq MS. 'Hit and run' transformation of mouse C127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology 1988; 164:39-47.
45. Bauer G, Kahl S, Sawhney IS, Hofler P, Gerspach R, Matz B. Transformation of rodent fibroblasts by herpes simplex virus: presence of morphological transforming region 1 (MTR 1) is not required for the maintenance of the transformed state. Int J Cancer 1992; 51:754-760.
46. Radaeva S, Li Y, Hacker HJ, Burger V, Kopp-Schneider A, Bannasch P. Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J Hepatol 2000; 33:580-600.
47. Su Q, Schroder CH, Otto G, Bannasch P. Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia. Mutat Res 2000; 462:365-380.
48. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Five years of sequential LAM to LAM+ADV therapy supresses HBV replication in most HBEAG-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Hepatology 2005; 42:983A.
49. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
50. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806.
51. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-264.
52. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-7561.
53. Bock TC, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivuaine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
54. Tanaka S, Ito T, Wands J. Neoplastic transformation induced by insulin receptor substrate 1 (IRS-1) overexpression requires an interaction with both Grb2 and Syp signaling molecules. J Biol Chem 1996; 271:14610- 14616.